Tectonic Therapeutic, Inc. Common Stock

Day range

$19.75 – $20.52

Open

$20.00

Prev close

$20.07

Volume

80.22K

Market cap

$392.36M

Shares out

19.55M

P/E

—

P/S

—

P/B

1.75

P/FCF

—

ROE

-38.3%

ROA

-36.2%

Debt/Equity

0.00

Div yield

0.00%

As of Oct 23, 2026

• Clinical trial resultsSep 29, 2026

  On September 29, 2026, Tectonic Therapeutic, Inc. issued a press release titled "Tectonic Therapeutic Announces Favorable Phase 1 Safety, Tolerability and PK Results for TX2100, a Novel Approach for the Treatment of Hereditary Hemorrhagic Telangiectasia (HHT)".

• Annual meeting resultsJun 10, 2026

  On June 8, 2026, Tectonic Therapeutic, Inc. (the "Company") held its 2026 Annual Meeting of Stockholders (the "Annual Meeting"). Timothy A. Springer and Stefan Vitorovic were elected as Class II directors, to hold office until the 2029 Annual Meeting of Stockholders and their successors are duly elected and qualified, or until their earlier death, resignation or removal.

• Director appointmentApr 23, 2026

  On April 23, 2026, the Board of Directors (the "Board") of Tectonic Therapeutic, Inc. (the "Company"), upon recommendation of the Nominating and Corporate Governance Committee of the Board, appointed Jessica Chutter as a member of the Board and as a member of the Audit Committee of the Board (the "Audit Committee"), effective as of the date of the Company's 2026 annual stockholder meeting. Ms. Chutter will serve as a Class III director whose term will expire at the Company's 2027 annual stockholder meeting. The Board has determined that Ms. Chutter qualifies as an "independent director" as determined in accordance with Rule 5605(a)(2) of the Nasdaq Rules and listing standards.

• Executive compensation changeFeb 24, 2026

  As a non-employee director of the Company, Dr. Nader is eligible to participate in the Company's non-employee director compensation policy, as amended (the "Compensation Policy"), pursuant to which he will receive, as of the Effective Date, (a) an annual cash retainer of $40,000 per year for service on the Board, (b) an additional $30,000 per year for his service as Chair of the Board and (c) a one-time initial equity award of options to purchase 20,400 shares of the Company's common stock (the "Initial Award").

• Investor presentationOct 30, 2025

  On October 29, 2025, Tectonic Therapeutic, Inc. (the 'Company') posted a presentation titled 'TX45 Phase 1b (Part B) PH-HFrEF Data Release Single Dose Hemodynamic Trial' on its website, a copy of which is attached as Exhibit 99.1 to this Current Report on Form 8-K.

Days to cover

8.1

Short interest

2.22M

Avg volume

275.51K

As of Sep 30, 2026 · reported to FINRA twice monthly.

• Tectonic (TECX) Q2 R&D Soars 142%
  neutralThe Motley Fool· Aug 7, 2025
• Tectonic Therapeutic Presents Complete Results for Positive Phase 1b Clinical Trial of TX45 in Patients with Group 2 Pulmonary Hypertension in HFpEF in Late-Breaking Presentation at ESC Heart Failure 2025
  positiveGlobeNewswire Inc.· May 17, 2025
• Tectonic Therapeutic Announces Positive Phase 1a Results in AHA 2024 Presentation for TX45, a Long-acting, Fc-Relaxin Fusion Protein
  positiveGlobeNewswire Inc.· Nov 11, 2024
• Tectonic Therapeutic Announces Favorable Phase 1a Safety, Tolerability and PK/PD Results for Lead Program TX45
  positiveGlobeNewswire Inc.· Sep 19, 2024